Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Añadir filtros

Base de datos
Intervalo de año
1.
BMJ Case Rep ; 14(1)2021 Jan 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1032286

RESUMEN

A 53-year-old man with diabetes came to the emergency department with fever and dry cough for 5 days, swelling of the left leg for 2 days, shortness of breath and chest pain for 1 hour. He had raised temperature, tachycardia, tachypnoea, reduced oxygen saturation and swollen tender left leg on examination. The frontal chest radiograph showed bilateral ground-glass opacities; he tested positive for COVID-19 with elevated D-dimer. The colour Doppler examination of the left leg revealed acute deep vein thrombosis (DVT) of the common femoral and the popliteal veins. The chest CT showed bilateral diffuse ground-glass opacities predominantly involving peripheral zones and the lower lobes. The CTPA revealed left pulmonary thromboembolism (PTE), treated with low-molecular-weight heparin. COVID-19 predominantly affects the respiratory system. DVT and PTE are common in COVID-19 but lethal. They should be diagnosed early by clinical and radiological examinations and treated promptly with anticoagulants.


Asunto(s)
/complicaciones , Embolia Pulmonar/etiología , Trombosis de la Vena/etiología , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Alanina/análogos & derivados , Alanina/uso terapéutico , Antibacterianos/uso terapéutico , Anticoagulantes/uso terapéutico , Antiparasitarios/uso terapéutico , Antivirales/uso terapéutico , /diagnóstico , /terapia , Angiografía por Tomografía Computarizada , Diabetes Mellitus Tipo 2/complicaciones , Doxiciclina/uso terapéutico , Vena Femoral , Productos de Degradación de Fibrina-Fibrinógeno , Glucocorticoides/uso terapéutico , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Ivermectina/uso terapéutico , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Terapia por Inhalación de Oxígeno , Vena Poplítea , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/terapia , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler en Color , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/terapia
2.
BMJ Case Rep ; 13(12)2020 Dec 28.
Artículo en Inglés | MEDLINE | ID: covidwho-1020894

RESUMEN

We present a previously healthy man in his 30s who presented with typical viral prodrome symptoms and worsening abdominal pain. He was found to have portal vein thrombosis, with extensive hypercoagulability workup performed. It was determined that the aetiology of thrombus was secondary to acute cytomegalovirus infection. The patient was started on anticoagulation therapy, with later clot resolution demonstrated on abdominal Doppler ultrasound and abdominal CT scan. Given the atypical presentation of this common virus, we performed a literature review of cytomegalovirus-associated portal vein thrombosis in healthy individuals; we found that most patients present with non-specific symptoms of fever and abdominal pain in the setting of a viral prodrome. This case and literature review suggest physicians must consider cytomegalovirus-associated portal vein thrombosis as a potential diagnosis when patients present with abdominal pain and viral symptoms. The literature highlights the need for a consensus on anticoagulation and antiviral therapy.


Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Vena Porta , Trombosis de la Vena/virología , Dolor Abdominal/etiología , Adulto , Anticoagulantes/uso terapéutico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/virología , Angiografía por Tomografía Computarizada , Infecciones por Citomegalovirus/inmunología , Humanos , Inmunocompetencia , Masculino , Vena Porta/diagnóstico por imagen , Ultrasonografía Doppler , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico
3.
Am J Case Rep ; 22: e927011, 2021 Jan 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1005105

RESUMEN

BACKGROUND Pandemic coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe respiratory symptoms are a hallmark of the disease, which may also include complications related to a hypercoagulable state and central nervous system involvement. These complications can occur during either the acute or the recovery phase. The cerebral involvement typically manifests as intracranial hypertension, intracerebral hemorrhage, diffuse encephalopathy, or cerebral venous thrombosis. The hemorrhagic form of cerebral venous thrombosis can be a diagnostic challenge and is treated by anticoagulation therapy, despite the existence of an intracerebral hemorrhage. This report describes a case of superficial cerebral venous thrombosis and intracerebral hematoma in a 48-year-old man weeks after recovering from the acute phase of SARSCoV-2 infection. CASE REPORT A 48-year-old man with a past medical history of SARS-CoV-2 infection confirmed by SARS-CoV-2 reverse-transcription polymerase chain reaction presented with left upper-limb numbness, weakness, and impaired positional sensorium. After initial stabilization, noncontrast computerized tomography and magnetic resonance imaging confirmed an intracerebral hemorrhage with underlying cerebral venous thrombosis. The patient was successfully treated with enoxaparin anticoagulation therapy, and symptoms improved over the following 12 days. CONCLUSIONS Central nervous system venous thrombosis is an atypical presentation of the hypercoagulable state primarily seen in younger patients, and it can occur in a delayed fashion after recovery from mild forms of COVID-19.


Asunto(s)
/complicaciones , Hemorragia Cerebral/diagnóstico por imagen , Hematoma/diagnóstico por imagen , Trombosis Intracraneal/diagnóstico por imagen , Trombosis de la Vena/diagnóstico por imagen , Anticoagulantes/uso terapéutico , Hemorragia Cerebral/virología , Enoxaparina/uso terapéutico , Hematoma/virología , Humanos , Trombosis Intracraneal/tratamiento farmacológico , Trombosis Intracraneal/virología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/virología
4.
Radiology ; 298(2): E70-E80, 2021 02.
Artículo en Inglés | MEDLINE | ID: covidwho-977565

RESUMEN

Background The association of pulmonary embolism (PE) with deep vein thrombosis (DVT) in patients with coronavirus disease 2019 (COVID-19) remains unclear, and the diagnostic accuracy of D-dimer tests for PE is unknown. Purpose To conduct meta-analysis of the study-level incidence of PE and DVT and to evaluate the diagnostic accuracy of D-dimer tests for PE from multicenter individual patient data. Materials and Methods A systematic literature search identified studies evaluating the incidence of PE or DVT in patients with COVID-19 from January 1, 2020, to June 15, 2020. These outcomes were pooled using a random-effects model and were further evaluated using metaregression analysis. The diagnostic accuracy of D-dimer tests for PE was estimated on the basis of individual patient data using the summary receiver operating characteristic curve. Results Twenty-seven studies with 3342 patients with COVID-19 were included in the analysis. The pooled incidence rates of PE and DVT were 16.5% (95% CI: 11.6, 22.9; I2 = 0.93) and 14.8% (95% CI: 8.5, 24.5; I2 = 0.94), respectively. PE was more frequently found in patients who were admitted to the intensive care unit (ICU) (24.7% [95% CI: 18.6, 32.1] vs 10.5% [95% CI: 5.1, 20.2] in those not admitted to the ICU) and in studies with universal screening using CT pulmonary angiography. DVT was present in 42.4% of patients with PE. D-dimer tests had an area under the receiver operating characteristic curve of 0.737 for PE, and D-dimer levels of 500 and 1000 µg/L showed high sensitivity (96% and 91%, respectively) but low specificity (10% and 24%, respectively). Conclusion Pulmonary embolism (PE) and deep vein thrombosis (DVT) occurred in 16.5% and 14.8% of patients with coronavirus disease 2019 (COVID-19), respectively, and more than half of patients with PE lacked DVT. The cutoffs of D-dimer levels used to exclude PE in preexisting guidelines seem applicable to patients with COVID-19. © RSNA, 2020 Supplemental material is available for this article. See also the editorial by Woodard in this issue.


Asunto(s)
/complicaciones , Embolia Pulmonar/complicaciones , Embolia Pulmonar/diagnóstico por imagen , Trombosis de la Vena/complicaciones , Trombosis de la Vena/diagnóstico por imagen , /sangre , Angiografía por Tomografía Computarizada/métodos , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Humanos , Embolia Pulmonar/sangre , Trombosis de la Vena/sangre
5.
Chest ; 158(5): 2130-2135, 2020 11.
Artículo en Inglés | MEDLINE | ID: covidwho-893673
7.
Clin Appl Thromb Hemost ; 26: 1076029620953217, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-733074

RESUMEN

Deep vein thrombosis (DVT) is prevalent in patients with coronavirus disease 2019 (COVID-19). However, the risk factors and incidence rate of DVT remains elusive. Here, we aimed to assess the incidence rate and risk factors of DVT. All patients diagnosed with COVID-19 and performed venous ultrasound by ultrasound deparment between December 2019 and April 2020 in Wuhan Jin Yin-tan hospital were enrolled. Demographic information and clinical features were retrospectively collected. Notably, a comparison between the DVT and the non-DVT groups was explored. The incidence rate of venous thrombosis was 35.2% (50 patients out of 142). Moreover, the location of thrombus at the proximal extremity veins was 5.6% (n = 8), while at distal extremity veins was 35.2% (n = 50) of the patients. We also noted that patients with DVT exhibited a high level of D-dimer (OR 10.9 (95% CI, 3.3-36.0), P < 0.001), were admitted to the intensive care unit (OR 6.5 (95% CI, 2.1-20.3), P = 0.001), a lower usage of the anticoagulant drugs (OR 3.0 (95% CI, 1.1-7.8), P < 0.001). Finally, this study revealed that a high number of patients with COVID-19 developed DVT. This was observed particularly in critically ill patients with high D-dimer levels who required no anticoagulant medication.


Asunto(s)
Anticoagulantes/uso terapéutico , Infecciones por Coronavirus/epidemiología , Mortalidad Hospitalaria/tendencias , Neumonía Viral/epidemiología , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/epidemiología , Adulto , Anciano , China , Estudios de Cohortes , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/terapia , Femenino , Hospitalización , Humanos , Incidencia , Unidades de Cuidados Intensivos/estadística & datos numéricos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/terapia , Cobertura de Afecciones Preexistentes , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Ultrasonografía Doppler/métodos , Trombosis de la Vena/tratamiento farmacológico
9.
J Clin Ultrasound ; 48(9): 522-526, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: covidwho-694861

RESUMEN

PURPOSE: The aim of this study was to evaluate the applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis (DVT) in patients infected with corona virus disease 2019 (COVID-19) with and without treatment with low molecular weight heparin (LMWH). METHODS: We retrospectively analyzed the records of deceased and surviving patients in whom ultrasonography detected or not a DVT, and in whom LMWH was or not prescribed. RESULTS: The incidence of DVT is higher in the deceased (33/35) than in the surviving (22/46) patients. LMWH was administered in a larger proportion of surviving (18/22) than of deceased (18/33) patients. D-dimer concentrations decreased in patients who received LMWH in both groups. CONCLUSIONS: There was a high incidence of DVT in patients who succumbed to COVID-19. Bedside ultrasonography can detect the presence of DVT as early as possible and help assessing the risk of venous thromboembolism, allowing early and reasonable use of LMWH.


Asunto(s)
Infecciones por Coronavirus/diagnóstico por imagen , Infecciones por Coronavirus/patología , Heparina de Bajo-Peso-Molecular/administración & dosificación , Neumonía Viral/diagnóstico por imagen , Neumonía Viral/patología , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/virología , Adulto , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Betacoronavirus/aislamiento & purificación , Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/diagnóstico , Esquema de Medicación , Femenino , Heparina de Bajo-Peso-Molecular/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/sangre , Pruebas en el Punto de Atención , Estudios Retrospectivos , Ultrasonografía/métodos , Trombosis de la Vena/tratamiento farmacológico
11.
Chest ; 158(5): 2130-2135, 2020 11.
Artículo en Inglés | MEDLINE | ID: covidwho-671133
12.
J Clin Neurosci ; 79: 30-32, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-665630

RESUMEN

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in December 2019, and is ongoing pandemic. While a majority of patients with SARS-CoV-2 infection shows asymptomatic or mild disease, hospitalized patients can develop critical condition, such as pneumonia, sepsis, and respiratory failure. Some cases deteriorate into sever systemic disease and multiorgan failure. Many patients of severe COVID-19 show hypercoagulable state and complicate with venous thromboembolism and atrial thrombosis. We herein reported a case of COVID-19 who developed cerebral venous thrombosis (CVT) co-incidence with pulmonary thromboembolism (PTE). A 56-year-old Japanese man was presented with fever and malaise and diagnosed with COVID-19. He was treated with ciclesonide and azithromycin, but his respiratory condition deteriorated. Thus, systemic corticosteroids and favipiravir were initiated and these treatments resulted in afebrile state, improving malaise and respiratory failure. However, he suddenly developed severe headache and vomiting with increased concentration of D-dimer. Brain CT and MRI showed typical images of CVT in the left transvers sinus and CT pulmonary angiography showed PE. Administration of unfractionated heparin followed by edoxaban treatment reduced the levels of D-dimer and improved his clinical presentation and thrombosis. Monitoring coagulopathy is important in COVID-19 patients and in case of venous thromboembolism, including cerebral venous system, appropriate anticoagulant therapy should be initiated.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Trombosis Intracraneal/etiología , Neumonía Viral/complicaciones , Trombosis de la Vena/etiología , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Heparina/uso terapéutico , Humanos , Trombosis Intracraneal/diagnóstico por imagen , Trombosis Intracraneal/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Pandemias , Piridinas/uso terapéutico , Tiazoles/uso terapéutico , Tomografía Computarizada por Rayos X , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico
13.
Am J Trop Med Hyg ; 103(2): 844-846, 2020 08.
Artículo en Inglés | MEDLINE | ID: covidwho-630202

RESUMEN

The aim of this study was to evaluate the occurrence of pulmonary embolism in returning travelers with hypoxemic pneumonia due to COVID-19. All returning travelers to Reunion Island with hypoxemic pneumonia due to COVID-19 underwent computed tomography pulmonary angiography (CTPA) and were included in the cohort. Thirty-five patients were returning travelers with hypoxemic pneumonia due to COVID-19 and had recently returned from one of the countries most affected by the COVID-19 outbreak (mainly from France and Comoros archipelago). Five patients (14.3%) were found to have pulmonary embolism and two (5.9%) were incidentally found to have deep vein thrombosis on CTPA. Patients with pulmonary embolism or deep vein thrombosis had higher D-dimer levels than those without pulmonary embolism or deep vein thrombosis (P = 0.04). Returning travelers with hypoxemic pneumonia due to COVID-19 should be systematically screened for pulmonary embolism.


Asunto(s)
Infecciones por Coronavirus/diagnóstico por imagen , Neumonía Viral/diagnóstico por imagen , Embolia Pulmonar/diagnóstico por imagen , Trombosis de la Vena/diagnóstico por imagen , Anciano , Anciano de 80 o más Años , Angiografía , Betacoronavirus , Comoras , Infecciones por Coronavirus/complicaciones , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Francia , Humanos , Hipoxia/virología , Pulmón/diagnóstico por imagen , Pulmón/patología , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/complicaciones , Embolia Pulmonar/virología , Reunión , Tomografía Computarizada por Rayos X , Viaje , Trombosis de la Vena/virología
14.
J Stroke Cerebrovasc Dis ; 29(8): 104989, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: covidwho-622312

RESUMEN

OBJECTIVE: Identify clinical and radiographic features of venous infarct as a presenting feature of COVID-19 in the young. BACKGROUND: SARS-CoV-2 infection causes hypercoagulability and inflammation leading to venous thrombotic events (VTE). Although elderly patients with comorbidities are at higher risk, COVID-19 may also cause VTE in a broader patient population without these risks. Neurologic complications and manifestations of COVID-19, including neuropathies, seizures, strokes and encephalopathy usually occur in severe established cases of COVID-19 infection who primarily present with respiratory distress. CASE DESCRIPTION: Case report of a 29-year-old woman, with no significant past medical history or comorbidities, presenting with new onset seizures. Further questioning revealed a one-week history of headaches, low-grade fever, mild cough and shortness of breath, diagnosed as COVID-19. Imaging revealed a left temporoparietal hemorrhagic venous infarction with left transverse and sigmoid sinus thrombosis treated with full dose anticoagulation and antiepileptics. CONCLUSION: Although elderly patients with comorbidities are considered highest risk for COVID-19 neurologic complications, usually when systemic symptoms are severe, this case report emphasizes that young individuals are at risk for VTE with neurologic complications even when systemic symptoms are mild, likely induced by COVID-19 associated hypercoagulable state.


Asunto(s)
Betacoronavirus/patogenicidad , Infarto Encefálico/virología , Infecciones por Coronavirus/virología , Neumonía Viral/virología , Trombosis de los Senos Intracraneales/virología , Trombosis de la Vena/virología , Adulto , Factores de Edad , Anticoagulantes/uso terapéutico , Anticonvulsivantes/uso terapéutico , Infarto Encefálico/diagnóstico por imagen , Infarto Encefálico/tratamiento farmacológico , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Femenino , Interacciones Microbiota-Huesped , Humanos , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/tratamiento farmacológico , Factores de Riesgo , Trombosis de los Senos Intracraneales/diagnóstico por imagen , Trombosis de los Senos Intracraneales/tratamiento farmacológico , Resultado del Tratamiento , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico
16.
AJNR Am J Neuroradiol ; 41(8): 1377-1379, 2020 08.
Artículo en Inglés | MEDLINE | ID: covidwho-608375

RESUMEN

There is growing evidence that Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has a neurotropic and neuroinvasive potential. In particular, neurologic complications associated with the infection by SARS-CoV-2 include strokes that may result from a dysregulated inflammatory response to the infection. We report an atypical deep cerebral vein thrombosis complicated with hemorrhagic venous infarction in a patient positive for SARS-CoV-2 with no risk factors for thrombosis.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Hemorragias Intracraneales/etiología , Trombosis Intracraneal/etiología , Neumonía Viral/complicaciones , Trombosis de la Vena/etiología , Anciano , Humanos , Hemorragias Intracraneales/diagnóstico por imagen , Trombosis Intracraneal/diagnóstico por imagen , Imagen por Resonancia Magnética , Masculino , Imagen Multimodal , Pandemias , Tomografía Computarizada por Rayos X , Trombosis de la Vena/diagnóstico por imagen
17.
J Thromb Thrombolysis ; 50(3): 604-607, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-574524

RESUMEN

Corona virus outbreak started in December 2019, and the disease has been defined by the World Health Organization as a public health emergency. Coronavirus is a source of deep venous thrombosis (DVT) due to complications such as over-coagulation, blood stasis, and endothelial damage. In this study, we report a 26-year-old pregnant woman with coronavirus who was hospitalized with a right ovarian vein thrombosis at Besat Hospital in Sanandaj. Risk classification for deep vein thrombosis (DVT) disease is of crucial importance for the forecast of coronavirus.


Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/virología , Ovario/irrigación sanguínea , Neumonía Viral/virología , Complicaciones Infecciosas del Embarazo/virología , Trombosis de la Vena/virología , Adulto , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Femenino , Interacciones Huésped-Patógeno , Humanos , Pandemias , Neumonía Viral/sangre , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Embarazo , Complicaciones Infecciosas del Embarazo/sangre , Complicaciones Infecciosas del Embarazo/diagnóstico , Factores de Riesgo , Trombosis de la Vena/sangre , Trombosis de la Vena/diagnóstico por imagen
18.
J Investig Med High Impact Case Rep ; 8: 2324709620931239, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-564936

RESUMEN

On December 31, 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province, China. The pneumonia was caused by a virus called SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2), which was later named coronavirus infectious disease 2019 (COVID-19). The symptoms most commonly reported by patients affected by COVID-19 include fever, dry cough, and shortness of breath. In this report, we present a case of a 57-year-old woman who presented to the clinic's infectious department with swelling, pain, warmth, and redness in the left leg who was treated with therapeutic heparin. There were no typical and distinguished symptoms of COVID-19, and she had no risk factor for deep vein thrombosis. Then chest X-ray revealed bilateral patchy ground-glass opacity, and computed tomography angiography was performed to rule out pulmonary thromboembolism, which showed no evidence of thrombosis. Left lower limb venous color Doppler ultrasound revealed dilatation and thrombosis in the external iliac and left iliac veins up to the level of the bifurcation of the common iliac veins, as well as thrombosis to the superficial and small saphenous veins. Because of ground-glass opacity and lymphopenia, nasal swabs were used for sampling, and SARS-CoV-2 nucleic acid was detected by reverse transcription polymerase chain reaction (RT-PCR). This case aims to arouse the medical staff's awareness of deep vein thrombosis as a clinical symptom of COVID-19 even if the patient has no typical symptoms of COVID-19.


Asunto(s)
Infecciones por Coronavirus/complicaciones , Linfopenia/etiología , Neumonía Viral/complicaciones , Trombosis de la Vena/etiología , Anticoagulantes/uso terapéutico , Antimaláricos/uso terapéutico , Antivirales/uso terapéutico , Betacoronavirus , Cloroquina/uso terapéutico , Técnicas de Laboratorio Clínico , Angiografía por Tomografía Computarizada , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/diagnóstico por imagen , Infecciones por Coronavirus/tratamiento farmacológico , Combinación de Medicamentos , Femenino , Heparina/uso terapéutico , Humanos , Vena Ilíaca/diagnóstico por imagen , Lopinavir/uso terapéutico , Pulmón/diagnóstico por imagen , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/diagnóstico por imagen , Neumonía Viral/tratamiento farmacológico , Embolia Pulmonar/diagnóstico , Radiografía Torácica , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ritonavir/uso terapéutico , Vena Safena/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler en Color , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA